EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer
2008
19075 Background: Probability of clinical benefit from EGFR tyrosine kinase inhibitors in previously treated NSCLC pts is strongly associated with the presence of EGFR mutation. However, the experi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI